Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25089651 | 0.89 | HSD11B1 (0.45) | KCNH2EPHX1EPHX2HTR4HTR3A | |
| SCHEMBL26330243 | 0.87 | HTR4 (0.41) | KCNH2HRH3EPHX1EPHX2HTR4 | |
| SCHEMBL26141946 | 0.86 | EPHX1 (0.32) | KCNH2HRH3EPHX1EPHX2HTR4 | |
| SCHEMBL24865912 | 0.86 | HTR4 (0.33) | KCNH2HRH3HTR4DPP4PREP | |
| SCHEMBL24941792 | 0.85 | NAMPT (0.34) | HRH3EPHX1EPHX2HTR4DPP4 | |
| SCHEMBL22302357 | 0.85 | HTR4 (0.43) | KCNH2HRH3EPHX1EPHX2HTR4 | |
| SCHEMBL23709475 | 0.81 | HTR4 (0.46) | KCNH2HRH3EPHX1EPHX2HTR4 | |
| SCHEMBL25089655 | 0.81 | NAMPT (0.47) | — | |
| SCHEMBL25101407 | 0.80 | FPR3 (0.42) | HRH3EPHX1EPHX2HTR4DPP4 | |
| SCHEMBL25089968 | 0.79 | NAMPT (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | KCNH2 4697/4885HRH3 2014/4885EPHX1 1508/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | KCNH2 4697/4885HRH3 2014/4885EPHX1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.